Hiroshi Nomoto

Loop profile ORCID

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 31

Top Venues

Journal of diabetes investigation

Endocrine journal

Diabetes, obesity & metabolism

Nature communications

Hokkaido University (PHD)

This page only lists publications with an associated author ORCID identifier.

Education History

Hokkaido University

Japan

PHD

Publications

Aika Miya, Akinobu Nakamura, Hiroshi Nomoto, Hiraku Kameda, Tatsuya Atsumi
Positive association between the proinsulin-to-C-peptide ratio and prolonged hyperglycemic time in type 2 diabetes. Endocrine journal 71 (4) (2024)
Aika Miya, Akinobu Nakamura, Hiroshi Nomoto, Hiraku Kameda, Tatsuya Atsumi
Positive association between the proinsulin-to-C-peptide ratio and prolonged hyperglycemic time in type 2 diabetes. Endocrine journal (2024)
Aika Miya, Akinobu Nakamura, Yuka Suzuki, Hiroshi Nomoto, Hiraku Kameda, Kyu Yong Cho, Tatsuya Atsumi
Frequency and determinants of lipid management target achievement in primary prevention of cardiovascular disease in type 2 diabetes. Diabetology international 15 (3) (2024)
Sho Furusawa, Hiroshi Nomoto, Chiho Oba-Yamamoto, Jun Takeuchi, Miki Ito, Hiroyoshi Kurihara, Shin Aoki, Aika Miya, Hiraku Kameda, Akinobu Nakamura, Tatsuya Atsumi
Real-world clinical evidence of oral semaglutide on metabolic abnormalities in subjects with type 2 diabetes: a multicenter retrospective observational study (the Sapporo-Oral SEMA study). Endocrine journal 71 (6) (2024)
Sho Furusawa, Hiroshi Nomoto, Chiho Oba-Yamamoto, Jun Takeuchi, Miki Ito, Hiroyoshi Kurihara, Shin Aoki, Aika Miya, Hiraku Kameda, Akinobu Nakamura, Tatsuya Atsumi
Real-world clinical evidence of oral semaglutide on metabolic abnormalities in subjects with type 2 diabetes: a multicenter retrospective observational study (the Sapporo-Oral SEMA study). Endocrine journal 71 (6) (2024)
Aika Miya, Akinobu Nakamura, Hiroshi Nomoto, Hiraku Kameda, Tatsuya Atsumi
Positive association between the proinsulin-to-C-peptide ratio and prolonged hyperglycemic time in type 2 diabetes. Endocrine journal 71 (4) (2024)
Aika Miya, Akinobu Nakamura, Hiroshi Nomoto, Hiraku Kameda, Tatsuya Atsumi
Positive association between the proinsulin-to-C-peptide ratio and prolonged hyperglycemic time in type 2 diabetes. Endocrine journal 71 (4) (2024)
Sho Furusawa, Hiroshi Nomoto, Chiho Oba-Yamamoto, Jun Takeuchi, Miki Ito, Hiroyoshi Kurihara, Shin Aoki, Aika Miya, Hiraku Kameda, Akinobu Nakamura, Tatsuya Atsumi
Real-world clinical evidence of oral semaglutide on metabolic abnormalities in subjects with type 2 diabetes: a multicenter retrospective observational study (the Sapporo-Oral SEMA study). Endocrine journal (2024)
Akihiro Takahashi, Hiroshi Nomoto, Kinnosuke Onishi, Satoru Manda, Aika Miya, Hiraku Kameda, Akinobu Nakamura, Tatsuya Atsumi
A comparative study of the effects of imeglimin add-on or metformin dose escalation on glycaemic variability in subjects with type 2 diabetes treated with low-dose metformin (MEGMI-CGM study). Diabetes, obesity & metabolism (2024)
Akihiro Takahashi, Hiroshi Nomoto, Kinnosuke Onishi, Satoru Manda, Aika Miya, Hiraku Kameda, Akinobu Nakamura, Tatsuya Atsumi
A comparative study of the effects of imeglimin add-on or metformin dose escalation on glycaemic variability in subjects with type 2 diabetes treated with low-dose metformin (MEGMI-CGM study). Diabetes, obesity & metabolism 26 (8) (2024)
Hiroshi Nomoto, Sho Furusawa, Hiroki Yokoyama, Yuka Suzuki, Rimi Izumihara, Yuki Oe, Kiyohiko Takahashi, Aika Miya, Hiraku Kameda, Kyu Yong Cho, Jun Takeuchi, Yoshio Kurihara, Akinobu Nakamura, Tatsuya Atsumi
Improvement of β-Cell Function After Switching From DPP-4 Inhibitors to Oral Semaglutide: SWITCH-SEMA2 Post Hoc Analysis. The Journal of clinical endocrinology and metabolism (2024)
Aika Miya, Akinobu Nakamura, Yuka Suzuki, Hiroshi Nomoto, Hiraku Kameda, Kyu Yong Cho, Tatsuya Atsumi
Frequency and determinants of lipid management target achievement in primary prevention of cardiovascular disease in type 2 diabetes. Diabetology international 15 (3) (2024)
Yuka Takahashi, Hiroshi Nomoto, Hiroki Yokoyama, Yoshinari Takano, So Nagai, Atsushi Tsuzuki, Kyu Yong Cho, Aika Miya, Hiraku Kameda, Jun Takeuchi, Shinji Taneda, Yoshio Kurihara, Tatsuya Atsumi, Akinobu Nakamura, Hideaki Miyoshi, null null
Improvement of glycaemic control and treatment satisfaction by switching from liraglutide or dulaglutide to subcutaneous semaglutide in patients with type 2 diabetes: A multicentre, prospective, randomized, open-label, parallel-group comparison study (SWITCH-SEMA 1 study). Diabetes, obesity & metabolism (2023)
Sho Furusawa, Hiroshi Nomoto, Hiroki Yokoyama, Yuka Suzuki, Atsushi Tsuzuki, Kiyohiko Takahashi, Aika Miya, Hiraku Kameda, Kyu Yong Cho, Jun Takeuchi, So Nagai, Shinji Taneda, Yoshio Kurihara, Akinobu Nakamura, Tatsuya Atsumi, null null
Glycaemic control efficacy of switching from dipeptidyl peptidase-4 inhibitors to oral semaglutide in subjects with type 2 diabetes: A multicentre, prospective, randomized, open-label, parallel-group comparison study (SWITCH-SEMA 2 study). Diabetes, obesity & metabolism (2023)
Hiroshi Nomoto, Kenichi Kito, Hiroshi Iesaka, Yuki Oe, Shinichiro Kawata, Kazuhisa Tsuchida, Shingo Yanagiya, Aika Miya, Hiraku Kameda, Kyu Yong Cho, Ichiro Sakuma, Naoki Manda, Akinobu Nakamura, Tatsuya Atsumi
Favorable Effect of Pemafibrate on Insulin Resistance and β-Cell Function in Subjects with Type 2 Diabetes and Hypertriglyceridemia: A Subanalysis of the PARM-T2D Study. Pharmaceutics 15 (7) (2023)
Hiroshi Nomoto, Yuka Takahashi, Yoshinari Takano, Hiroki Yokoyama, Kazuhisa Tsuchida, So Nagai, Aika Miya, Hiraku Kameda, Kyu Yong Cho, Akinobu Nakamura, Tatsuya Atsumi
Effect of Switching to Once-Weekly Semaglutide on Non-Alcoholic Fatty Liver Disease: The SWITCH-SEMA 1 Subanalysis. Pharmaceutics 15 (8) (2023)
Hiroshi Nomoto, Sho Furusawa, Akinobu Nakamura, Jun Takeuchi, So Nagai, Hiroki Yokoyama, Ichiro Sakuma, Shinji Taneda, Yoshio Kurihara, Shin Aoki, Aika Miya, Hiraku Kameda, Kyu Yong Cho, Tatsuya Atsumi, Hideaki Miyoshi
Effects of switching from a dipeptidyl peptidase-4 inhibitor to oral semaglutide on glucose metabolism in patients with type 2 diabetes: protocol for a multicentre, prospective, randomised, open-label, parallel-group comparison study (the SWITCH-SEMA 2 study). BMJ open 12 (5) (2022)
Yuri Ofuji, Hiroshi Nomoto, Aika Miya, Hiraku Kameda, Kyu Yong Cho, Akinobu Nakamura, Hideaki Miyoshi, Tatsuya Atsumi
Urethral injury related to peri-urethral abscess as a complication of self-catheterization in an older patient with type 2 diabetes. Geriatrics & gerontology international 22 (10) (2022)
Yuki Oe, Hiroshi Nomoto, Akinobu Nakamura, Saki Kuwabara, Yuka Takahashi, Ayano Yasui, Rimi Izumihara, Aika Miya, Hiraku Kameda, Kyu Yong Cho, Tatsuya Atsumi, Hideaki Miyoshi
Switching from Insulin Degludec plus Dipeptidyl Peptidase-4 Inhibitor to Insulin Degludec/Liraglutide Improves Glycemic Variability in Patients with Type 2 Diabetes: A Preliminary Prospective Observation Study. Journal of diabetes research 2022 (2022)
Kei Yokozeki, Hiroshi Nomoto, Tatsuya Atsumi
Diabetic Chorea. Journal of general internal medicine 37 (10) (2022)
Yuki Oe, Hiroshi Nomoto, Aika Miya, Hiraku Kameda, Kyu Yong Cho, Akinobu Nakamura, Hideaki Miyoshi, Tatsuya Atsumi
Letter to the Editor Regarding Efficacy of IDegLira Versus IDegAsp Therapy in Patients with Type 2 Diabetes: A Randomized Crossover Study by isCGM. Advances in therapy (2022)
Hiroshi Nomoto, Akihiro Takahashi, Akinobu Nakamura, Hiroyoshi Kurihara, Jun Takeuchi, So Nagai, Shinji Taneda, Aika Miya, Hiraku Kameda, Kyu Yong Cho, Hideaki Miyoshi, Tatsuya Atsumi
Add-on imeglimin versus metformin dose escalation regarding glycemic control in patients with type 2 diabetes treated with a dipeptidyl peptidase-4 inhibitor plus low-dose metformin: study protocol for a multicenter, prospective, randomized, open-label, parallel-group comparison study (MEGMI study). BMJ open diabetes research & care 10 (6) (2022)
Tomonori Sekizaki, Hiraku Kameda, Hiroshi Nomoto, Kyu Yong Cho, Akinobu Nakamura, Kiyohiko Takahashi, Arina Miyoshi, Norio Wada, Jun Takeuchi, So Nagai, Hideaki Miyoshi, Tatsuya Atsumi
Dipeptidyl peptidase-4 inhibitor might exacerbate Graves' disease: A multicenter observational case-control study. Journal of diabetes investigation 12 (11) (2021)
Kyu Yong Cho, Hiroshi Nomoto, Akinobu Nakamura, Shinichiro Kawata, Hajime Sugawara, Jun Takeuchi, So Nagai, Kazuno Omori, Kazuhisa Tsuchida, Aika Miya, Ikumi Shigesawa, Kenichi Tsuchida, Shingo Yanagiya, Hiraku Kameda, Hiroki Yokoyama, Shinji Taneda, Yoshio Kurihara, Shin Aoki, Naoki Nishimoto, Tatsuya Atsumi, Hideaki Miyoshi
Improved time in range and postprandial hyperglycemia with canagliflozin in combination with teneligliptin: Secondary analyses of the CALMER study. Journal of diabetes investigation 12 (8) (2021)
Kyu Yong Cho, Akinobu Nakamura, Kazuno Omori, Takahiro Takase, Aika Miya, Kohei Yamamoto, Hiroshi Nomoto, Hiraku Kameda, Shinji Taneda, Yoshio Kurihara, Shin Aoki, Tatsuya Atsumi, Hideaki Miyoshi
Favorable effect of sodium-glucose cotransporter 2 inhibitor, dapagliflozin, on non-alcoholic fatty liver disease compared with pioglitazone. Journal of diabetes investigation 12 (7) (2020)
Chiho Oba-Yamamoto, Jun Takeuchi, Akinobu Nakamura, Ryoko Takikawa, Ayano Ozaki, Hiroshi Nomoto, Hiraku Kameda, Kyu Yong Cho, Tatsuya Atsumi, Hideaki Miyoshi
Combination of alcohol and glucose consumption as a risk to induce reactive hypoglycemia. Journal of diabetes investigation 12 (4) (2020)
Koki Chiba, Hiroshi Nomoto, Akinobu Nakamura, Kyu Yong Cho, Kumiko Yamashita, Yui Shibayama, Aika Miya, Hiraku Kameda, Yoshio Kurihara, Shin Aoki, Tatsuya Atsumi, Hideaki Miyoshi
Sodium-glucose cotransporter 2 inhibitors reduce day-to-day glucose variability in patients with type 1 diabetes. Journal of diabetes investigation 12 (2) (2020)
Chiara Montemurro, Hiroshi Nomoto, Lina Pei, Vishal S Parekh, Kenny E Vongbunyong, Suryakiran Vadrevu, Tatyana Gurlo, Alexandra E Butler, Rohan Subramaniam, Eleni Ritou, Orian S Shirihai, Leslie S Satin, Peter C Butler, Slavica Tudzarova
IAPP toxicity activates HIF1α/PFKFB3 signaling delaying β-cell loss at the expense of β-cell function. Nature communications 10 (1) (2019)
Chiara Montemurro, Hiroshi Nomoto, Lina Pei, Vishal S Parekh, Kenny E Vongbunyong, Suryakiran Vadrevu, Tatyana Gurlo, Alexandra E Butler, Rohan Subramaniam, Eleni Ritou, Orian S Shirihai, Leslie S Satin, Peter C Butler, Slavica Tudzarova
Publisher Correction: IAPP toxicity activates HIF1α/PFKFB3 signaling delaying β-cell loss at the expense of β-cell function. Nature communications 10 (1) (2019)
Takahiro Takase, Akinobu Nakamura, Chiho Yamamoto, Hiroshi Nomoto, Aika Miya, Midori Dannoura, Kyu Yong Cho, Yoshio Kurihara, Naoki Manda, Shin Aoki, Tatsuya Atsumi, Hideaki Miyoshi
Improvement in treatment satisfaction after switching from liraglutide to dulaglutide in patients with type 2 diabetes: A randomized controlled trial. Journal of diabetes investigation 10 (3) (2018)
Kiyohiko Takahashi, Kyu Yong Cho, Akinobu Nakamura, Aika Miya, Arina Miyoshi, Chiho Yamamoto, Hiroshi Nomoto, Hirokatsu Niwa, Kiyohito Takahashi, Naoki Manda, Yoshio Kurihara, Shin Aoki, Yoichi M Ito, Tatsuya Atsumi, Hideaki Miyoshi
Should sulfonylurea be discontinued or maintained at the lowest dose when starting ipragliflozin? A multicenter observational study in Japanese patients with type 2 diabetes. Journal of diabetes investigation 10 (2) (2018)

Hiroshi Nomoto.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Hiroshi Nomoto